02.02.01. Investigación y comunicación científica

Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey

2026-09-18T05:51:00Z

Implementation of quantitative HBsAg testing in clinical microbiology laboratories in Spain: Results from a national GEHEP-SEIMC survey Chaves-Blanco, Lucía; Illescas-López, Marta; Fuentes, Ana; Carracedo, Raquel; Delgado-Iribarren, Alberto; Vázquez-Blanquino, Alberto; Blázquez, Ana-María; Saez, Ruth; Miqueleiz, Ana; de-los-Reyes-Vidal, María; Tosco, Tomas; Gómez, César; Moldes, Luz; Calvo, Noelia; Pérez-Rodríguez, Lucía; Trigo, Matilde; Dolores-Ocete, María; Alcaraz, María-Jesús; Asuncion-Iborra, María; García, Julio; Joaquin-Blas, José; María-Vallejo, Aldara; Alberola-Romano, Ana; Illescas, Soledad; Rodríguez, Juan-Carlos; Alonso, Roberto; Cámara, Margarita; Dolores-Navarro, María; Luisa-Núñez, María; del-Amor-Espín, María-Jesús; Beteta, Alicia; Cascales-Alcolea, Eva; Miguel-Soria, Luis; Gacinuno, Sonsoles; Sandoval, Marta; Cortizo, Sandra; Ordóñez, Patricia; Liendo, Paloma; Pérez, Mercedes; Álvarez-Arguelles, Marta; García, Fernando; Rodríguez, Inmaculada; Gómez, Carmen; Elorduy, Luis; Hernández-Febles, Melisa; González-Praetorius, Alejandro; Liebana, Carmen; Lourdes-Molina, María; Salicio, Yolanda; Macho, Mikele; Becerril, Berta; Franco-Álvarez, Francisco; Falcés-Romero, Iker; Algarete, Sonia; Jose-Gude, María; Pablo, Daniel; Magdalena-Lara, María; Montiel, Natalia; Freyre, Carolina; Galán, Juan-Carlos; Pérez, Ana-Belén; Lorenzo, Belén; Fraile, Pablo; Sánchez-Yebra, Waldo; Viciana, Isabel; Sampedro, Antonio; del-Carmen-Lozano, María; Domínguez-Castano, Ana; Ramírez, Encarnación; Beltran, Inocencio; Martin, Teresa; Puerta, Antonio; Tajada, Pilar; Panes, Paula; Martín, Adrián; Hurtado, Juan-Carlos; López-Braos, Javier; Arjona, Francisco; Miro, Elisenda; Ruiz, Montserrat; Ramírez, Mercedes; Gil-Fortuno, María; González-Pellicer, Rosa; Acedo, Juan-Manuel; Anel-Pedroche, Jorge; Infante-Urrios, Ana; Domínguez, Victoria; Aran-Toha, Guillermo; Mrtinez-Macias, Olalla; Orta-Mira, Nieves; Torres-Sopena, Luis; Cantudo, Purificación; Araceli-Hernández, María; Arroyo-Serrano, Teresa; Rando, Ariadna; Garrido, Marta; Fernández, Gema; de-Salazar, Adolfo; Aguilera, Antonio; García, Federico

Trends in the management and coding of chronic kidney disease in Spain: cross-sectional analyses of real-life data with a 5-year interval

2026-09-18T05:51:10Z

Trends in the management and coding of chronic kidney disease in Spain: cross-sectional analyses of real-life data with a 5-year interval Santamaria, Rafael; Pimentel, Belén; Palacios, Beatriz; Hernández, Ignacio; Escobar, Carlos; Gorostidi, Manuel; Cebrián-Cuenca, Ana-María; Alcazar, Roberto

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV.

2026-09-18T05:51:04Z

CABO-CHANCE study: A real-life world study of Cabotegravir plus Rilpivirine long-acting intramuscular in ART-experienced people with HIV. Hidalgo-Tenorio, Carmen; Aguilera-García, María; de-los-Santos, Ignacio; Ruiz-Sancho, A-; Rivero, A; López-Lirola, A; Omar, M; Romero, A; Bernal-Morell, Enrique; Martínez, O; López, T; Sorni, P; García-Ocana, P; Moreno, S; Sanjoaquin, I; Blanco, J-R; García, C BACKGROUND: This study of people with HIV (PWH) receiving CAB + RPV LAI evaluated its effectiveness, safety, and impact on inflammatory markers, body fat/lean mass distributions, quality of life, sleep, health satisfaction, and stigma experience over 1 y. METHODS: A prospective, longitudinal, multicentre study was conducted in 15 hospitals and enrolled between June 2023 and January 2024. It included virologically suppressed PWH (HIV-1 RNA <50 c/mL for ?6 months) switched from oral antiretroviral therapy to CAB + RPV LAI. Anthropometrics, CD4/CD8 counts, viral load, creatinine clearance, lipid levels, and inflammatory markers were recorded at baseline and 12, 28, 52 weeks. Patient-reported outcomes were gathered using the WHOQOL-HIV-BREF, HIV stigma scale for use in Spain, Pittsburgh Sleep Quality Index, and questionnaires on health satisfaction and adverse events. A subpopulation underwent to whole-body dual energy X-ray absorptiometer (DEXA). RESULTS: Among 269 PWH (mean age 45.6 y; 89.2% male), 240 completed 52-week follow-up, 14 (5.2%) were lost to follow-up, six (2.2%) withdrew consent, 5 (1.9%) were discontinued for adverse events, and one (0.4%) had virological failure (week 12). Snapshot effectiveness was 88.8% (intention-to-treat) and 97.5% (per-protocol). No oral bridging was required. CD4/CD8 ratio (P = 0.0001) and creatinine clearance (P = 0.0001) increased, d-dimer decreased at week 12 (P = 0.001), and BMI modestly increased (P = 0.046). No changes in total/regional fat or lean mass by DEXA (n = 56). Stigma (P = 0.029) and adverse events (P = 0.001) improved. CONCLUSIONS: In this real-world cohort, CAB + RPV LAI was highly effective and safe, was associated with a possible favourable immunologic response, a transient reduction in inflammation, and reduced perceived stigma over 1 y.

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023)

2026-09-18T05:52:25Z

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023) Muñoz-Baez, Paloma; Illescas-López, Marta; de-Salazar, Adolfo; Falcés-Romero, Iker; Pinto, Adriana; Portilla, Irene; Masia, Mar; Peraire, Joaquim; Alemán-Valls, María-Remedios; Sanchiz, Marta; Iborra-Bendicho, María-Asunción; Baza, Begoña; Aguilera, Antonio; Olalla, Julian; Espinosa, Nuria; Iribarren, José-Antonio; Gisbert, Laura; Imaz, Arkaitz; Montero, Marta; Navarro-Marcotegui, María; Suárez-García, Inés; Riera, Melchor; Pérez-Elias, María-Jesús; Galán, Juan-Carlos; García-Fraile, Lucio-Jesus; Sanz, José; Ibarra-Ugarte, Sofía; Bernal-Morell, Enrique; Blanco, José-Ramon; Navarro, Gemma; Martínez-Madrid, Onofre; Viciana-Ramos, María-Isabel; Mohamen-Balghata, Mohamed-Omar; Delgado, Elena; Thompson, Michael-M; Moreno, Cristina; Fuentes, Ana; García, Federico BACKGROUND: While surveillance drug resistance mutations (SDRMs) remain essential for monitoring transmitted drug resistance (TDR), the clinical impact of transmitted resistance for current first-line regimens has become increasingly important. We aimed to update estimates of TDR in Spain and assess its clinical impact over time. METHODS: This is a nationwide observational study within the CoRIS cohort. We estimated the prevalence of SDRMs and clinically meaningful resistance (CMR) among antiretroviral therapy (ART)-naïve individuals with baseline genotypic resistance testing in 2022-2023 and evaluated annual trends in CMR to first-line regimens from 2007 to 2023. Clinically meaningful resistance was defined as Stanford HIVDB resistance level ? 3. RESULTS: In 2022-2023, 1028 individuals were included; 82.8% were male, 63.2% MSM, and 72.2% subtype B. Surveillance drug resistance mutation prevalence was 14.4% (95% CI 12.2%-16.9%), driven mainly by NNRTI-SDRMs, while INSTI-SDRMs remained rare [0.5% (95% CI 0.1%-1.5%)]; CMR to recommended first-line regimens was very low. Over 2007-2023, CMR declined markedly, coinciding with adoption of second-generation integrase inhibitors. Rilpivirine-associated resistance mutations were detected in 7.0%, largely due to E138A (4.8%). M184V was detected in 0.8%; 6 of 8 cases occurred in persons with current or prior oral pre-exposure prophylaxis (PrEP), although numbers were small. CONCLUSIONS: In Spain, TDR remains stable, but its clinical impact on first-line regimens has markedly declined. These findings support Test & Treat strategies and immediate ART initiation with contemporary triple- or dual-drug regimens, while highlighting the need for targeted resistance assessment for rilpivirine-containing regimens and further research on prior PrEP exposure and selected NRTI resistance patterns.